- Recommendation ID
- MTG21/1
- Question
- Research is recommended to address uncertainties about the claimed patient and system benefits of the ReCell Spray-On Skin system. Clinical outcomes should include time to 95% healing, length of hospital stay, cosmetic appearance of the scar and function of the burned area, compared with standard care.
- Any explanatory notes
(if applicable) - As relevant databases and registers are available, the research might include analysis of data generated from these. NICE will explore the development of appropriate further evidence, in collaboration with the technology sponsor and with clinical and academic partners, and will update this guidance if and when new and substantive evidence becomes available.
Source guidance details
- Comes from guidance
- The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury
- Number
- MTG21
- Date issued
- November 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 06/01/2015 |